Issue 4, 2022

Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic

Abstract

Covering: 1993 to 2021 (mainly 2017–2021)

Alzheimer's and Parkinson's diseases are neurodegenerative conditions affecting over 50 million people worldwide. Since these disorders are still largely intractable pharmacologically, discovering effective treatments is of great urgency and importance. These conditions are characteristically associated with the aberrant deposition of proteinaceous aggregates in the brain, and with the formation of metastable intermediates known as protein misfolded oligomers that play a central role in their aetiology. In this Highlight article, we review the evidence at the physicochemical, cellular, animal model and clinical levels on how the natural products squalamine and trodusquemine offer promising opportunities for chronic treatments for these progressive conditions by preventing both the formation of neurotoxic oligomers and their interaction with cell membranes.

Graphical abstract: Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic

Article information

Article type
Highlight
Submitted
28 Jun 2021
First published
26 Oct 2021
This article is Open Access
Creative Commons BY license

Nat. Prod. Rep., 2022,39, 742-753

Squalamine and trodusquemine: two natural products for neurodegenerative diseases, from physical chemistry to the clinic

R. Limbocker, S. Errico, D. Barbut, T. P. J. Knowles, M. Vendruscolo, F. Chiti and M. Zasloff, Nat. Prod. Rep., 2022, 39, 742 DOI: 10.1039/D1NP00042J

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements